Founded in 1978, Biogen is a global biotechnology company headquartered in Cambridge, Massachusetts, with a major manufacturing presence in Research Triangle Park, North Carolina. The company focuses on delivering transformative medicines for patients with neurological diseases, drawing on nearly 50 years of scientific expertise.
Biogen's core therapeutic areas span neurology, immunology, and rare diseases. Its pipeline includes first-in-class treatments for conditions such as multiple sclerosis, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy, lupus, and postpartum depression.
The company employs over 4,000 people in the United States, including close to 2,500 in research and development and more than 1,500 in manufacturing roles in North Carolina. Biogen describes its culture as combining rigorous science with a commitment to patients, encouraging bold scientific risk-taking.